Testing a new model for cancer genetics counseling in metastatic breast cancer patients
Official title: Efficacy of Point Of Service Testing in Metastatic Breast Cancer
Run by University of Kansas Medical Center · NCT03983577 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests a new way to provide genetic counseling right at the doctor's office for people with HER2 negative metastatic breast cancer to see if it helps them feel more satisfied and get better support.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Kansas Medical Center Academic / other |
| Locations | 1 site (Kansas City, Kansas) |
| Trial ID | NCT03983577 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with HER2 negative metastatic breast cancer who can provide informed consent and are enrolled in the parent registry study.
✕Probably not a fit
Patients who have undergone genetic testing for BRCA mutations after 2013 or those with psychiatric conditions that limit compliance may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a point of service delivery model for genetic counseling in patients with metastatic breast cancer who have been referred for hereditary cancer genetic testing. The approach aims to provide timely and accessible genetic counseling directly at the point of care. Participants must have HER2 negative metastatic breast cancer and be enrolled in a parent registry study. The study seeks to determine if this innovative model improves patient outcomes and satisfaction with genetic counseling services.
Why it matters
Potential benefit: If successful, this approach could enhance access to genetic counseling for metastatic breast cancer patients, leading to better-informed treatment decisions.
How similar studies have gone: While there is limited data on this specific point of service model, similar approaches in genetic counseling have shown promise in improving patient access and outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent. * Able to speak and read in the English language. * Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer. * Participants must be enrolled in the parent registry study. Exclusion Criteria: * Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed. * Psychiatric illness/social situations that would limit compliance with study requirements.
Where it's running
-
The University of Kansas Cancer Center, Westwood Campus
Kansas City, Kansas, United States Recruiting
Study contacts
- Principal investigator: Lauren Nye, MD — University of Kansas
- Study coordinator: CT Nurse Navigator
- Email: ctnursenav@kumc.edu
- Phone: 913-945-7552
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Precision oncology navigation with expert genomic review to guide therapy and survival
This tests whether a centralized precision oncology navigator and expert review of NGS results increase the use of genome-informed therapies for people with stage IV breast, lung, colorectal, or bladder cancer.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
Treatment for Oligometastatic Breast Cancer
This study is testing whether adding a special type of radiation therapy to standard treatment can help women with a few metastatic breast cancer spots live longer and feel better.
-
Identifying biomarkers for endocrine therapy resistance in lobular breast cancer
This study is trying to find markers in the blood that can help doctors understand how well patients with lobular breast cancer respond to hormone therapy.
-
Evaluating INX-315 for advanced cancer treatment
This study is testing a new oral medication called INX-315 to see if it can safely help people with advanced cancers, including breast and ovarian cancer, who haven't responded to other treatments.
-
Digital health coaching for cancer survivors
This study is testing whether a digital health coaching program can help cancer survivors feel better and improve their health after finishing treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.